Last Updated : November 22, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Cosentyx | Secukinumab | Arthritis, psoriatic | Reimburse with clinical criteria and/or conditions | Complete | ||
Cosentyx | secukinumab | Hidradenitis suppurativa | Reimburse with clinical criteria and/or conditions | Active | ||
Cotellic | Cobimetinib | Metastatic melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Cresemba | isavuconazole | Treatment of invasive aspergillosis and mucormycosis | Reimburse with clinical criteria and/or conditions | Complete | ||
Crysvita | burosumab | Treatment of X-Linked Hypophosphatemia | Reimburse with clinical criteria and/or conditions | Complete | ||
Crysvita | burosumab | Treatment of X-Linked Hypophosphatemia | Reimburse with clinical criteria and/or conditions | Active | ||
Cubicin | Daptomycin | Skin and skin structure infections & bacteremia | Do not list | Complete | ||
Cuvposa | glycopyrrolate | chronic severe drooling, neurologic (pediatric) | Do not reimburse | Complete | ||
Cymbalta | Duloxetine hydrochloride | Pain, Neuropathic, Diabetic | List with clinical criteria and/or conditions | Complete | ||
Cymbalta | Duloxetine hydrochloride | Depressive, Major Disorder (MDD) | Do not list | Complete | ||
Cyramza | Ramucirumab | Metastatic Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Cyramza | Ramucirumab | Cancelled | ||||
Cystadrops | cysteamine | Corneal cystine crystal deposits | Reimburse with clinical criteria and/or conditions | Complete | ||
Daklinza | Daclatasvir | Hepatitis C, Chronic | List with clinical criteria and/or conditions | Complete | ||
Daklinza | daclatasvir | Hepatitis C, Chronic | Reimburse with clinical criteria and/or conditions | Complete | ||
Darzalex | Daratumumab | Multiple Myeloma (second-line) | Reimburse with clinical criteria and/or conditions | Complete | ||
Darzalex | Daratumumab | Rd for MM | Reimburse with clinical criteria and/or conditions | Complete | ||
Darzalex | daratumumab | Light chain (AL) amyloidosis | Reimburse with clinical criteria and/or conditions | Complete | ||
Darzalex | daratumumab | Multiple myeloma, eligible for autologous stem cell transplant | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | ||
Darzalex | Daratumumab | Multiple Myeloma | Do not reimburse | Complete | ||
Darzalex | Daratumumab | BMP for Multiple Myeloma (newly diagnosed) | Reimburse with clinical criteria and/or conditions | Complete | ||
Darzalex SC | daratumumab | Multiple myeloma, eligible for autologous stem cell transplant | Active | |||
Daurismo | Glasdegib | Acute Myeloid Leukemia (AML) | Do not reimburse | Complete | ||
Daxas | Roflumilast | Chronic obstructive pulmonary disease | Do not list | Complete | ||
Daybue | trofinetide | Rett syndrome (RTT) | Active |